DRRX DURECT CORP Product Launches 8-K Filing 2024 - Trial Announcement DURECT Corporation announced the design of its Phase 3 trial for larsucosterol, aimed at treating severe alcohol-associated hepatitis.Get access to all SEC 8-K filings of the DURECT CORP